KIT Mutations, Melanoma
2002695
Ordering Recommendation
Predicts response to tyrosine kinase inhibitor (TKI) therapy.
Mnemonic
KIT MELAN
Methodology
Polymerase Chain Reaction/Sequencing
Performed
Varies
Reported
10-12 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Tumor tissue.  
Specimen Preparation
Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Transport tissue block or 5 unstained 5-micron slides. (Min: 4 slides) Transport block and/or slide(s) in a tissue transport kit (ARUP supply # 47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787.  
Storage/Transport Temperature
Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.  
Unacceptable Conditions
Less than 25 percent tumor. Specimens fixed/processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives. Decalcified specimens.  
Remarks
Include surgical pathology report.  
Stability
Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable  
Reference Interval
By report  
Interpretive Data
Refer to report.

See Compliance Statement B: www.aruplab.com/CS  
Note
 
CPT Code(s)
88381; 81404
Components
Component Test Code*Component Chart Name
2002148Block ID
2002694KIT Mutation, Melanoma Interpretation
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • c-KIT
  • CD117 KIT
  • cKIT
  • KIT exons 9, 11,13, and 17
  • TKI resistance determination